abstract |
The present invention relates to a method for treating a T cell mediated inflammatory immune disease or a T cell mediated hypersensitivity disease, comprising an effective amount of a compound that inhibits EZH2 and / or EZH1, or a pharmaceutically acceptable salt thereof. It relates to a method comprising administering to a human in need thereof. |